
Patient-Focused Drug Development Meetings: Smart Practices from Community Leaders

Models for Financing Antibiotic Development to Address Antimicrobial Resistance

A Conversation with Scott Gottlieb, Commissioner, U.S. Food and Drug Administration

A Conversation with FDA Commissioner Stephen Hahn

Emily Kramer-Golinkoff: LeadersLink Capstone

The Future of Rare Disease R&D: Protecting Progress, Achieving Access

From Passengers to Co-Pilots: Patient Roles Expand

Electronic Medical Records: A Bridge to Faster Cures

Milken Institute Launches “Early Warning” Initiative for Emerging Pandemic Threats as COVID-19 Cases Increase

Milken Institute statement on ARPA-H inclusion in FY2022 spending bill

Comments on FDA’s Draft Guidance for Industry, Investigators, and Other Stakeholders on Decentralized Clinical Trials for Drugs, Biological Products, and Devices - Docket ID FDA-2022-D-2870
